CDT Neutralizing Antibodies for IBS Diagnosis and Prevention

Resolve Bottlenecks,
Find Innovative SolutionsGenerate Solutions

Solution Overview

Problem

There is a need for effective diagnosis, treatment, and prevention of irritable bowel syndrome (IBS) and non-ulcer dyspepsia (NUD), as existing methods have not established a clear association with cytolethal distending toxin (CDT) and these conditions, despite evidence suggesting a link between initial food poisoning and their pathophysiology.

Innovation Solution

A method involving the detection of CDT or its markers in biological samples to diagnose and predict the likelihood of IBS and NUD, and the use of CDT inhibitors or neutralizers, such as specific antibodies, to reduce the likelihood of developing these conditions, along with administering compositions that elicit a specific immune response to prevent IBS.

Engineering Contradictions & Design Principles

VSEngineering Contradiction Analysis

1Measurement precision

If CDT detection methods are developed to diagnose IBS and NUD, then diagnostic accuracy for these conditions is improved, but the complexity of the diagnostic process increases

Engineering Contradiction:

Improvediagnostic accuracyVSAvoiddiagnostic process complexity

Core Design Contradiction:

Measurement precisionVSDevice complexity

Solution Approach 1:

The patent uses antibodies as intermediary substances that specifically bind to CDT markers in biological samples. These antibodies serve as mediators between the CDT toxin and detection systems, enabling accurate detection of CDT presence without requiring direct complex analysis of the toxin itself. The antibody-CDT complex formation provides a reliable basis for diagnosis while simplifying the overall detection process.

Inventive Principle:

Principle #24Intermediary (Mediator)

2Reliability

If CDT inhibitors or neutralizers are used to prevent IBS and NUD, then the effectiveness of prevention is improved, but the complexity of treatment protocols increases

Engineering Contradiction:

Improveprevention effectivenessVSAvoidtreatment protocol complexity

Core Design Contradiction:

ReliabilityVSDevice complexity

Solution Approach 1:

The patent converts the harmful effect of CDT into a beneficial diagnostic and therapeutic tool. By detecting CDT markers and using CDT-specific antibodies for neutralization, the harmful toxin becomes the target of a precise intervention strategy. The same CDT presence that causes disease is used to guide prevention and treatment, transforming the pathological agent into a focal point for therapeutic action.

Inventive Principle:

Principle #22Blessing in disguise (Convert harm into benefit)

Solution Approach 2:

CDT inhibitors and neutralizing antibodies serve as intermediary substances that block the interaction between CDT and host cells. These intermediaries bind to CDT and prevent its harmful effects without requiring direct modification of the toxin or the host cell, thereby simplifying the therapeutic mechanism while maintaining high prevention effectiveness.

Inventive Principle:

Principle #24Intermediary (Mediator)

3Measurement precision

If specific antibodies against CDT are developed, then the specificity of CDT detection is improved, but the difficulty of antibody production increases

Engineering Contradiction:

Improvedetection specificityVSAvoidantibody production ease

Core Design Contradiction:

Measurement precisionVSEase of manufacture

Solution Approach 1:

The patent employs preliminary immunization of host animals with CDT or CDT fragments to pre-produce specific antibodies before they are needed for detection or therapy. This preliminary action of immunization allows the host immune system to naturally generate high-affinity, specific antibodies that can then be harvested and used for diagnostic and therapeutic purposes, reducing the technical difficulty of producing specific antibodies.

Inventive Principle:

Principle #10Preliminary action

Applied Scientific Principles

This section explains which scientific principles are used to turn an abstract innovation direction into a practical engineering solution.

Function Achieved in This Case

The method allows for accurate diagnosis and potential prevention of IBS and NUD by correlating CDT presence with condition likelihood and using CDT inhibitors to neutralize its harmful effects, providing a targeted therapeutic approach.

Implementation Method 1

a purified antibody that binds specifically to cytolethal distending toxin (CDT) a subunit of CDT

Methodology Applied

Scientific EffectAntibody-antigen binding:

Data Source

PatentUS10527621B2Antibody to cytolethal distending toxin of Campylobacter jejuni

Publication Date: 2020.01.07 CEDARS SINAI MEDICAL CENT

AI summary

The present invention describes methods for preventing IBS, reducing the likelihood of developing IBS and/or treating IBS by administering CDT inhibitors and/or CDT neutralizers to a subject in need thereof. The present invention also describes methods of eliciting a specific immune response and methods of vaccinating a subject to prevent IBS or to reduce the likelihood of developing or having IBS. The present invention further describes methods of diagnosing IBS by detecting the presence or absence of CDT or a CDT marker in a subject.